Zoetis Inc. (NYSE:ZTS) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds. Bank of America Cites Zoetis Inc.'s (ZTS) Strong Q4 Performance and Fiscal 2026 Outlook Zoetis Inc. (NYSE:ZTS) tops our list for being one of the cheap pharmaceutical stocks. TheFly reported on February 13 that Bank of America raised its price target for ZTS to $140 from $135 and maintained a Neutral rating on the shares. The upgraded target was supported by the company's fiscal 2026 projection and fourth- ...

Core Insights - Sanofi has filed its Form 20-F with the U.S. SEC and its "Document d'Enregistrement Universel" with the French AMF, which includes the Annual Financial Report [1] - These documents contain complete audited financial statements and are available on the company's website as well as the SEC and AMF websites [1] Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives and fostering growth through innovative medicines and vaccines [2] - The company leverages its understanding of the immune system to develop treatments that benefit millions globally, with a commitment to addressing urgent healthcare, environmental, and societal challenges [2] - Sanofi is publicly traded on EURONEXT under the ticker SAN and on NASDAQ under the ticker SNY [2]

Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the company’s website:https://www.sanofi.com/en/investors/reports-an ...

Core Viewpoint - Zoetis Inc. is a leading animal health company facing challenges in stock performance and revenue growth due to various market and company-specific factors [2][5]. Company Overview - Zoetis Inc. has a market capitalization of $56.3 billion and specializes in animal health products, including medicines, vaccines, and diagnostic solutions for both livestock and companion animals [1]. Stock Performance - Over the past 52 weeks, Zoetis shares have decreased by 27.5%, underperforming the S&P 500 Index, which gained 12.2% during the same period [2]. - Year-to-date, Zoetis shares have gained 1.3%, contrasting with a slight decline in the S&P 500 Index [2]. Competitive Analysis - Zoetis has also lagged behind the State Street Health Care Select Sector SPDR ETF, which has seen a 5.4% increase over the past year [3]. Financial Performance - In Q3 2025, Zoetis reported revenue of approximately $2.4 billion, reflecting a modest year-over-year increase of about 1% [6]. - Analysts project a 7.1% year-over-year growth in EPS for the fiscal year 2025, estimating it to reach $6.34 [6]. Analyst Ratings - The consensus rating among 17 analysts covering Zoetis is a "Moderate Buy," with eight "Strong Buy" ratings, one "Moderate Buy," and eight "Holds" [6]. - This rating configuration has become less bullish compared to three months ago, when there were 11 "Strong Buy" ratings [7]. Recent Downgrade - On January 22, 2026, Piper Sandler analyst David Westenberg downgraded Zoetis from "Overweight" to "Neutral" and reduced the price target from $190 to $135 [7].

Core Viewpoint - AstraZeneca plans to invest $15 billion in China by 2030 to enhance its medicines manufacturing and research and development capabilities [1] Company Investment - The investment is aimed at expanding AstraZeneca's operations in China, focusing on both manufacturing and R&D [1] Timeline - The investment will be made over the course of the next seven years, concluding in 2030 [1]

Core Insights - The article highlights the efforts made by the National Health Commission and other departments to address the challenges in grassroots drug supply, particularly in rural areas, by optimizing the drug supply environment [1] Group 1: Drug Supply Challenges - Grassroots healthcare, especially in rural areas, faced issues such as limited drug variety, slow delivery times, poor coordination, and unreasonable prescriptions [1] - The city’s health commission has implemented a "central pharmacy" and "prescription review center" to ensure comprehensive coverage in the county, addressing the drug supply challenges effectively [1] Group 2: Drug Management Mechanism - A tight-knit drug management mechanism has been established within the medical community, breaking down barriers between county, township, and village levels, leading to a unified drug selection and procurement process [2] - The innovative "1+3" supply guarantee mechanism includes inventory warning, emergency allocation, and drug shortage registration to meet personalized medication needs, resulting in an 80% increase in drug availability at township medical institutions and a 40% increase at village clinics [2] Group 3: Delivery Efficiency - The integration of resources within the medical community has improved drug delivery efficiency, with a 7.3% increase in the rate of drugs arriving within three days and a reduction in average delivery time by one day [3] - The previous issues of drug shortages have been resolved, with most drugs now arriving within 2 to 3 days, enhancing the reliability of drug supply for healthcare providers [3] Group 4: Prescription Safety - A dual review mechanism combining intelligent and manual checks has been established to ensure prescription safety, with a prescription review center set up in all counties, leading to a 23% increase in prescription approval rates [4] - The increase in prescription safety has positively impacted the willingness of the public to seek medical care, with grassroots medical services accounting for 68% of total diagnoses, ranking third in the province [4] Group 5: Future Directions - The city plans to continue deepening the reform of drug management within the medical community, enhancing the entire supply, delivery, and regulatory chain to improve grassroots drug security and pharmaceutical service capabilities [5]

Core Viewpoint - Johnson & Johnson (NYSE: JNJ) has provided a strong 2026 outlook, surpassing Wall Street expectations despite facing significant challenges, including a drug pricing agreement and tariff-related costs [2][3]. Financial Performance - For 2026, Johnson & Johnson anticipates sales between $99.5 billion and $100.5 billion, exceeding analyst projections of approximately $98.9 billion [3]. - The company expects full-year earnings per share to be in the range of $11.43 to $11.63, slightly above the consensus estimate of $11.45 [3]. Management Outlook - CEO Joaquin Duato expressed optimism during the earnings call, indicating that the company expects to achieve faster growth in 2026 compared to 2025 and aims for double-digit growth by the end of the decade [4]. Business Operations - Johnson & Johnson operates across the healthcare sector, developing and selling a diverse range of products, including pharmaceuticals and medical devices [4]. Challenges - The drug pricing agreement with the Trump administration is projected to cost the company "hundreds of millions of dollars," alongside an expected $500 million in tariff-related costs impacting its medical devices segment [2][3].

Core Insights - Zoetis has experienced a significant decline in stock price, dropping nearly 40% after a decade of outperforming the S&P 500 with a 480% increase [1][6] - The company's current price-to-earnings (P/E) ratio is at a historic low of 21, down from an average of 39 since 2013, indicating a potential long-term buying opportunity [2] - Zoetis remains a leader in the animal healthcare industry, with a strong pipeline of new therapies and a commitment to annual major market approvals [3] Company Performance - The company has 12 new therapies with "blockbuster" potential, which could generate over $100 million in sales, and currently has 17 blockbuster drugs [4] - Zoetis targets chronic kidney failure, oncology, and cardiology for dogs and cats, representing a $5 billion market opportunity against annual sales of $9.3 billion [4] - The company has consistently outperformed the global animal healthcare market, which is expected to grow at 5% to 6% annually through 2035, with Zoetis achieving 8% annualized sales growth since 2013 [5] Investment Considerations - Despite the recent stock decline, Zoetis' operations remain robust, supported by a promising pipeline and a steadily growing dividend [6] - The company does not require double-digit sales growth to be an outperformer, but it may achieve closer to that figure than market expectations [5]

Market Overview - Futures have reversed modest overnight gains, with S&P futures down 0.1% and Nasdaq futures down 0.3% as small caps outperform for a record 12th day in a row [1] - The market mood remains shaky, with a significant drop in liquidity as top of book collapsed 60% overnight [4] - Gold continues to hit new highs, approaching $4,900 per ounce, while bond yields are 1-2 basis points lower [1][8] Corporate News - Biohaven (BHVN) rises 3% after an upgrade to outperform by RBC due to supportive data [5] - Halliburton (HAL) climbs 2% after reporting fourth-quarter adjusted earnings per share that beat analyst estimates [5] - Kraft Heinz (KHC) declines 5% as Berkshire Hathaway may sell some or all of its stake in the company [5] - Nathan's Famous (NATH) rises 8% after Smithfield Foods agreed to buy the company for $102 per share [5] - Netflix (NFLX) falls 7% after forecasting first-quarter earnings below analyst estimates and pausing share buybacks [5] Economic Indicators - The US economic calendar includes October construction spending and December pending home sales, with expectations of a 0.1% increase and a 0.25% decrease respectively [18][38] - Inflation in the UK rose to 3.4% in December, slightly above expectations, driven by higher tobacco prices and airfares [27] Geopolitical Developments - President Trump's speech at the World Economic Forum is anticipated to address various topics, including trade and tariffs, amid ongoing tensions regarding Greenland [6][30] - The Supreme Court is set to hear arguments regarding Trump's ability to fire Federal Reserve Governor Lisa Cook, coinciding with a criminal investigation into Fed Chair Jerome Powell [11][25] Sector Performance - European stocks drifted lower, with the Stoxx 600 down 0.6%, weighed down by financials and tech, while materials and luxury names outperformed [13][26] - The Russell 2000 is outperforming the Magnificent Seven by more than 10% year-to-date, indicating a rotation in market leadership [9]

Core Viewpoint - Dividend stocks tend to outperform non-dividend-paying stocks over the long term, making them a valuable addition to any long-term investment portfolio [1] Group 1: Visa - Visa is recognized as a strong investment, favored by notable investors like Warren Buffett, due to its straightforward business model of processing transactions and charging fees [3] - The company benefits from a strong competitive advantage, including a well-known brand and significant network effects, making it difficult for merchants to ignore Visa as a payment option [4] - Visa has promising growth prospects, with trillions of dollars still transacted in cash and checks annually, alongside the growth of e-commerce driving demand for digital payments [6] - The company has increased its dividend by 379% over the past decade, despite a forward yield of 0.8%, indicating its reliability as a long-term hold [7] Group 2: Novartis - Novartis has a strong track record of increasing dividends for 28 consecutive years, reflecting its stable and reliable business model [8] - The pharmaceutical company boasts a diverse portfolio with over 10 products generating annual sales exceeding $1 billion, allowing it to mitigate revenue losses from patent expirations [9] - Novartis is well-positioned to benefit from increasing healthcare spending, particularly due to an aging population, and offers a forward dividend yield of 2.8% [12] Group 3: Meta Platforms - Meta Platforms is recognized for its growth potential, supported by a vast ecosystem of over 3.5 billion daily active users across its platforms [13] - The company leverages extensive user data to enhance targeted advertising, solidifying its position in the digital ads market [14] - Meta is investing in artificial intelligence to improve user engagement and streamline ad processes, which could enhance its revenue generation capabilities [15] - Although it has just initiated a dividend with a yield of 0.3%, Meta's increasing earnings and cash flow suggest potential for future dividend growth [18]